Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder

Trends in Molecular Medicine

Volumn 9, Issue 10, 2003, Pages 450-453

  Brooks, Doug A ^a   Kakavanos, Revecca ^a   Hopwood, John J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GLUCOSIDASE INHIBITOR; ENZYME; GALSULFASE; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; NEUTRALIZING ANTIBODY;

ABDOMINAL PAIN; ABSCESS; ANGIONEUROTIC EDEMA; BACKACHE; BURNING SENSATION; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CYANOSIS; DEVELOPMENTAL DISORDER; DIARRHEA; EDEMA; ENZYME METABOLISM; ENZYME REPLACEMENT; FATIGUE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNE RESPONSE; LYSOSOME STORAGE DISEASE; MORBIDITY; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; PATHOGENESIS; PROTEIN INDUCTION; PROTEIN TARGETING; PRURITUS; RASH; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; URTICARIA; VERTIGO; VOMITING;

EID: 0142153023     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2003.08.004     Document Type: Review

References (19)

1. Meikle, P.J. et al. (1999) Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281, 249-254
2. Hers, H.G. (1963) α-glucosidase deficiency in generalized glycogen-storage disease (Pompe's Disease). Biochem. J. 86, 11
3. De Duve, C. (1964) From cytases to lysosomes. Fed. Proc. 23, 1045-1054
4. Brady, R.O. et al. (1974) Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med. 291, 989-993
5. Rosenberg, M. et al. (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93, 2081-2088
6. Kakavanos, R. et al. (2003) Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 361, 1608-1613
7. Aldurazyme® product sheet 5649 (4/03). Genzyme Corporation, Cambridge, MA, USA
8. Amalfitano, A. et al. (2001) Recombinant human acid a-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3, 132-138
9. Eng, C.M. et al. (2001) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345, 9-16
10. Fabrazyme® product sheet 5031 (4/03). Genzyme Corporation, Cambridge, MA, USA
11. Replagal® product sheet (date authorised 03/08/2001). TKT Europe-5S AB, Rinkebyvagen 11B, SE 182 36 Danderyd, Sweden
12. Aryplase® press release 14/03/2003. Available from the BioMarin Pharmaceutical Inc. web site at http://www.biomarinpharm.com
13. Brooks, D.A. (1999) Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. 68, 268-275
14. Cerezyme® product sheet 4668 (2/02). Genzyme Corporation, Cambridge, MA, USA
15. Brooks, D.A. et al. (1997) Enzyme-replacement therapy in mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. Biochim. Biophys. Acta 1361, 203-216
16. Turner, C.T. et al. (2000) Enzyme-replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of a α-L-iduronidase in immunized rats. Mol. Genet. Metab. 69, 277-285
17. Brady, R.O. et al. (1997) Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 100, E11
18. Iduronate-2-sulphatase press release 16/10/02. Available from http:// www.tktx.com
19. Van Den Hout, J.M.P. et al. (2001) Enzyme therapy for Pompe disease with recombinant α-glucosidase from rabbit milk. J. Inherit. Metab. Dis. 24, 266-274